We wanted to officially welcome our CLC bio colleagues to the QIAGEN family. CLC bio is a global leader in DNA sequence data analysis and will be a strategic complement to Ingenuity’s solutions for biological interpretation and reporting. Ingenuity has worked collaboratively with CLC for a number of years already and we are looking forward to deepening our relationship with them.
Based in Aarhus, Denmark, CLC bio was founded in 2005 and has grown to employ nearly 100 people. Today, its software is in use by some 250,000 scientists in 2,000 organizations across more than 100 countries around the globe.
The analysis and interpretation of biological data has become a rate-limiting factor in the broad adoption of high-throughput sequencing for a number of applications, particularly in clinical diagnostics. It’s clear that today’s sequencing systems are capable of cost-effectively producing high-quality data, but customers want more than just a lot of data from sequencing – they want a complete, robust workflow providing advanced visualizations and powerful insights.
We are very pleased to be part of the QIAGEN family and look forward to working with our colleagues in Germany and Denmark to create efficient, seamless, and cost-effective sample-to-insight NGS workflows for use on any sequencing platform.